The economic impact of galantamine vs placebo: An analysis based on functional capacity in a Swedish cohort study

References

• Ballard C, Gauthier S, Corbett A, et al. Alzheimer’s disease. Lancet 2011;377:1019–31.
   PubMed Web of Science ®Google Scholar
• Alzheimer’s Disease International. World Alzheimer report 2009. London: Alzheimer’s Disease International; 2009
   Google Scholar
• Wimo A, Winblad B, Jonsson L. The worldwide societal costs of dementia: estimates for 2009. Alzheimers Dement 2010;6:98–103
   PubMed Web of Science ®Google Scholar
• Alzheimer's Association. 2011 Alzheimer's disease facts and figures. Alzheimers Dement 2011;7:208–44
   PubMed Web of Science ®Google Scholar
• Wimo A, Johannson L, Jönsson L. The societal costs of dementia and the number of demented in Sweden 2005 [report in Swedish]. Stockholm: Socialstyrelsen; 2007
   Google Scholar
• Wimo A, Jonsson L, Gustavsson A, et al. The economic impact of dementia in Europe in 2008-cost estimates from the Eurocode project. Int J Geriatr Psychiatry 2011;26:825–32
   PubMed Web of Science ®Google Scholar
• Wimo A, Jönsson L. The societal costs of dementia [report in Swedish]. Sweden: Socialstyrelsen; 2001
   Google Scholar
• Cappell J, Herrmann N, Cornish S, et al. The pharmacoeconomics of cognitive enhancers in moderate to severe Alzheimer's disease. CNS Drugs 2010;24:909–27
   PubMed Web of Science ®Google Scholar
• Whitehouse PJ, Winblad B, Shostak D, et al. First International Pharmacoeconomic Conference on Alzheimer's Disease: report and summary. Alzheimer Dis Assoc Disord 1998;12:266–80
   PubMed Web of Science ®Google Scholar
• Jönsson L, Jonsson B, Wimo A, et al. Second International Pharmacoeconomic Conference on Alzheimer' s Disease. Alzheimer Dis Assoc Disord 2000;14:137–40
   PubMedGoogle Scholar
• Nordberg G, Wimo A, Jonsson L, et al. Time use and costs of institutionalised elderly persons with or without dementia: results from the Nordanstig cohort in the Kungsholmen Project–a population based study in Sweden. Int J Geriatr Psychiatry 2007;22:639–48
   PubMedGoogle Scholar
• Cummings JL, Back C. The cholinergic hypothesis of neuropsychiatric symptoms in Alzheimer's disease. Am J Geriatr Psychiatry 1998;6:S64–78.
   PubMed Web of Science ®Google Scholar
• Bores GM, Huger FP, Petko W, et al. Pharmacological evaluation of novel Alzheimer's disease therapeutics: acetylcholinesterase inhibitors related to galanthamine. J Pharmacol Exp Ther 1996;277:728–38
   PubMed Web of Science ®Google Scholar
• Samochocki M, Hoffle A, Fehrenbacher A, et al. Galantamine is an allosterically potentiating ligand of neuronal nicotinic but not of muscarinic acetylcholine receptors. J Pharmacol Exp Ther 2003;305:1024–36
   PubMed Web of Science ®Google Scholar
• Loy C, Schneider L. Galantamine for Alzheimer's disease and mild cognitive impairment. Cochrane Database Syst Rev 2006;25(1):CD001747
   Google Scholar
• Tariot PN, Solomon PR, Morris JC, et al. A 5-month, randomized, placebo-controlled trial of galantamine in AD. The Galantamine USA-10 Study Group. Neurology 2000;54:2269–76
   Google Scholar
• Rockwood K, Mintzer J, Truyen L, et al. Effects of a flexible galantamine dose in Alzheimer's disease: a randomised, controlled trial. J Neurol Neurosurg Psychiatry 2001;71:589–95
   PubMed Web of Science ®Google Scholar
• Erkinjuntti T, Kurz A, Gauthier S, et al. Efficacy of galantamine in probable vascular dementia and Alzheimer's disease combined with cerebrovascular disease: a randomised trial. Lancet 2002;359:1283–90
   PubMed Web of Science ®Google Scholar
• Brodaty H, Corey-Bloom J, Potocnik FC, et al. Galantamine prolonged-release formulation in the treatment of mild to moderate Alzheimer's disease. Dement Geriatr Cogn Disord 2005;20:120–32
   PubMed Web of Science ®Google Scholar
• Raskind MA, Peskind ER, Wessel T, et al. Galantamine in AD: a 6-month randomized, placebo-controlled trial with a 6-month extension. The Galantamine USA-1 Study Group. Neurology 2000;54:2261–8
   Google Scholar
• Wilcock GK, Lilienfeld S, Gaens E. Efficacy and safety of galantamine in patients with mild to moderate Alzheimer's disease: multicentre randomised controlled trial. Galantamine International-1 Study Group. BMJ 2000;321:1445–9
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Brinck P, Bergvall N, et al. Predictors of costs of care in Alzheimer's disease: a multinational sample of 1222 patients. Alzheimers Dement 2011;7:318–27
   PubMed Web of Science ®Google Scholar
• Gélinas I, Gauthier L, McIntyre M, et al. Development of a functional measure for persons with Alzheimer's disease: the disability assessment for dementia. Am J Occup Ther 1999;53:471–81
   PubMed Web of Science ®Google Scholar
• Nordberg G, von SE, Kareholt I, et al. The amount of informal and formal care among non-demented and demented elderly persons-results from a Swedish population-based study. Int J Geriatr Psychiatry 2005;20:862–71
   PubMed Web of Science ®Google Scholar
• Wimo A, Johannson L, Jönsson L. The societal costs of dementia and the number of demented in Sweden 2005. Report No. 2007-123-32 [report in Swedish]. Stockholm: Socialstyrelsen; 2007
   Google Scholar
• Wimo A, Johannson L, Jönsson L. Did dementia prevalence and social costs change between 2000 and 2005? [report in Swedish]. Läkartidningen 2009;106:1277–82
   PubMedGoogle Scholar
• Wimo A, Nordberg G. Validity and reliability of assessments of time. Comparisons of direct observations and estimates of time by the use of the resource utilization in dementia (RUD)-instrument. Arch Gerontol Geriatr 2007;44:71–81
   Google Scholar
• Katz S, Akpom CA. Index of ADL. Med Care 1976;14(5 Suppl):116–8
   PubMed Web of Science ®Google Scholar
• Louis ED. Functional correlates of lower cognitive test scores in essential tremor. Mov Disord 2010;25:481–5
   PubMed Web of Science ®Google Scholar
• Al-Ani AN, Flodin L, Soderqvist A, et al. Does rehabilitation matter in patients with femoral neck fracture and cognitive impairment? A prospective study of 246 patients. Arch Phys Med Rehabil 2010;91:51–7
   PubMed Web of Science ®Google Scholar
• Lee DH, Buth KJ, Martin BJ, et al. Frail patients are at increased risk for mortality and prolonged institutional care after cardiac surgery. Circulation 2010;121:973–8
   PubMed Web of Science ®Google Scholar
• Marra TA, Pereira DS, Faria CD, et al. Influence of socio-demographic, clinical and functional factors on the severity of dementia. Arch Gerontol Geriatr 2011;53:210–5
   PubMed Web of Science ®Google Scholar
• Gustavsson A, Jonsson L, Rapp T, et al. Differences in resource use and costs of dementia care between European countries: baseline data from the ICTUS study. J Nutr Health Aging 2010;14:648–54
   PubMed Web of Science ®Google Scholar
• Richmond R, Law J, Kay-Lambkin F. Higher blood pressure associated with higher cognition and functionality among centenarians in Australia. Am J Hypertens 2011;24:299–303
   PubMed Web of Science ®Google Scholar
• Manton KG, Corder L, Stallard E. Chronic disability trends in elderly United States populations: 1982-1994. Proc Natl Acad Sci U S A 1997;94:2593–8
   PubMed Web of Science ®Google Scholar
• Sano M, Wilcock GK, Van BB, et al. The effects of galantamine treatment on caregiver time in Alzheimer's disease. Int J Geriatr Psychiatry 2003;18:942–50
   PubMedGoogle Scholar
• Folstein MF, Folstein SE, McHugh PR. "Mini-mental state". A practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975;12:189–98
   PubMed Web of Science ®Google Scholar
• Jönsson L, Lindgren P, Wimo A, et al. Costs of mini mental state examination-related cognitive impairment. Pharmacoeconomics 1999;16:409–16
   PubMed Web of Science ®Google Scholar
• Jönsson L, Andreasen N, Kilander L, et al. Patient- and proxy-reported utility in Alzheimer disease using the EuroQoL. Alzheimer Dis Assoc Disord 2006;20:49–55
   PubMed Web of Science ®Google Scholar
• Sano M, Ernesto C, Thomas RG, et al. A controlled trial of selegiline, alpha-tocopherol, or both as treatment for Alzheimer's disease. The Alzheimer's Disease Cooperative Study. N Engl J Med 1997;336:1216–22
   PubMed Web of Science ®Google Scholar
• Knopman D, Schneider L, Davis K, et al. Long-term tacrine (Cognex) treatment: effects on nursing home placement and mortality, Tacrine Study Group. Neurology 1996;47:166–77
   PubMed Web of Science ®Google Scholar
• Mesterton J, Wimo A, By A, et al. Cross sectional observational study on the societal costs of Alzheimer's disease. Curr Alzheimer Res 2010;7:358–67
   PubMed Web of Science ®Google Scholar
• Garfield FB, Getsios D, Caro JJ, et al. Assessment of Health Economics in Alzheimer's Disease (AHEAD): treatment with galantamine in Sweden. Pharmacoeconomics 2002;20:629–37
   PubMed Web of Science ®Google Scholar
• Wallin AK, Gustafson L, Sjogren M, et al. Five-year outcome of cholinergic treatment of Alzheimer's disease: early response predicts prolonged time until nursing home placement, but does not alter life expectancy. Dement Geriatr Cogn Disord 2004;18:197–206
   PubMedGoogle Scholar
• Wimo A, Winblad B, Engedal K, et al. An economic evaluation of donepezil in mild to moderate Alzheimer's disease: results of a 1-year, double-blind, randomized trial. Dement Geriatr Cogn Disord 2003;15:44–54
   PubMed Web of Science ®Google Scholar
• Jönsson L, Lindgren P, Wimo A, et al. The cost-effectiveness of donepezil therapy in Swedish patients with Alzheimer's disease: a Markov model. Clin Ther 1999;21:1230–40
   PubMed Web of Science ®Google Scholar
• Wimo A, Karlsson G, Nordberg A, et al. Treatment of Alzheimer disease with tacrine: a cost-analysis model. Alzheimer Dis Assoc Disord 1997;11:191–200
   PubMed Web of Science ®Google Scholar